Ibumix is developing a new class of liquid crystal-based excipients designed to address fundamental constraints in solubility, stability, and formulation performance across modern drug products.
We are building a model-driven, scientifically rigorous platform positioned to become a foundational layer in pharmaceutical development.
The Structural Problem
Drug discovery has advanced significantly, yet formulation science remains constrained by legacy excipient systems.
A large proportion of APIs—particularly BCS Class II and IV—are limited by poor solubility, instability, and unpredictable behaviour.
This results in slower development, increased risk, and reduced therapeutic potential.
The Core Insight
The performance of an API is not solely defined by its chemistry, but by the environment in which it exists.
Engineering that environment represents a significant and under explored opportunity in pharmaceutical development.
Our Solution
Ibumix is developing engineered liquid crystal systems that create structured, tunable environments for APIs.
These systems are designed to improve solubility, stabilise formulations, and enable more predictable performance.
Platform Overview
The Ibumix™ Platform integrates:
- Liquid crystal architecture design
- Iterative experimental validation
Where We Are
Ibumix is currently in pre-commercial development, focused on foundational R&D, modelling, early data generation, and IP creation.
Why It Matters
If successful, this platform could expand API viability, reduce formulation risk, and enable next-generation therapeutics.